Cellectar Biosciences, Inc. (NASDAQ:CLRB) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

Separately, Zacks Investment Research upgraded Cellectar Biosciences from a “sell” rating to a “hold” rating in a report on Friday, August 25th.

Cellectar Biosciences (NASDAQ CLRB) traded up 0.61% during midday trading on Friday, hitting $1.65. The company had a trading volume of 55,531 shares. The firm’s market cap is $22.97 million. Cellectar Biosciences has a 52-week low of $1.12 and a 52-week high of $3.47. The stock has a 50 day moving average of $1.59 and a 200 day moving average of $1.88.

Cellectar Biosciences (NASDAQ:CLRB) last issued its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. On average, analysts anticipate that Cellectar Biosciences will post ($0.92) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/cellectar-biosciences-inc-clrb-upgraded-by-valuengine-to-sell/1536912.html.

A hedge fund recently raised its stake in Cellectar Biosciences stock. Vanguard Group Inc. boosted its position in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 31.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 147,208 shares of the biopharmaceutical company’s stock after buying an additional 35,482 shares during the period. Vanguard Group Inc. owned 1.09% of Cellectar Biosciences worth $240,000 as of its most recent SEC filing. 2.63% of the stock is currently owned by institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.

Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.